Smith & Nephew (SNN) Stock
Key stats
- Market cap
- $13.04B
- Price / Earnings ratio
- 21.9x
- EPS (TTM)
- $1.48
- Volume
- Loading
- 52-week high
- $37.09
- 52-week low
- $26.12
Source: third-party data provider, as of November 10, 2026
Compare with SNN
Recent news

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
SNN

Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
SNN

Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
SNN

Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
SNN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 60.22
- MACD 12/26/9
- 0.85
- EMA 9 of MACD
- 0.74
- MACD histogram
- 0.11
- SMA 50
- $28.55
- Price above SMA 50
- EMA 50
- $29.34
- Price above EMA 50
- SMA 200
- $31.02
- Price above SMA 200
- EMA 200
- $30.77
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.62 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
SNN

Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
SNN

Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
SNN

Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
SNN

UBS cuts Smith & Nephew target on competitive threats to three franchises
UBS cuts Smith & Nephew target on competitive threats to three franchises
SNN

SNN Advances Surgical Robotics Through Imperial College Partnership
SNN Advances Surgical Robotics Through Imperial College Partnership
SNN

Smith & Nephew shares slip on CFO's departure
Smith & Nephew shares slip on CFO's departure
SNN

Smith & Nephew drops 3.5% as finance chief quits
Smith & Nephew drops 3.5% as finance chief quits
SNN

Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery
Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery
SNN

Smith & Nephew SNATS Q2 Earnings Call Highlights
Smith & Nephew SNATS Q2 Earnings Call Highlights
SNN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Smith & Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Deepak S. Nath Ph.D. | CEO & Director | 1972 |
| Mr. Pierre Palassian | Interim CFO, Senior VP of Finance & Group Controller | — |
| Mr. Paul Connolly | President of Global Operations | 1968 |
| Emily Heaven | Head of Investor Relations | — |
| Ms. Helen Barraclough | Group General Counsel & Company Secretary | 1979 |
| Ms. Alison Parkes | Chief Compliance Officer & Compliance APAC | 1972 |
| Mr. Charles Reynolds | Head of Corporate Communication | — |
| Dr. Ajay Dhankhar Ph.D. | Chief Corporate Development & Strategy Officer | 1971 |
| Ms. Elga Lohler | Chief Human Resources Officer | 1968 |
| Dr. Vasant Padmanabhan Ph.D. | President Research & Development, ENT and Emerging Markets | 1967 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 10, 2026
Technical indicators
- RSI 14
- 60.22
- MACD 12/26/9
- 0.85
- EMA 9 of MACD
- 0.74
- MACD histogram
- 0.11
- SMA 50
- $28.55
- Price above SMA 50
- EMA 50
- $29.34
- Price above EMA 50
- SMA 200
- $31.02
- Price above SMA 200
- EMA 200
- $30.77
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- -
- Average
- -
- High
- -
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.0 | +7.5 | ||||||||||
| 2022 | -3.6 | +4.5 | -8.6 | +0.3 | +1.9 | -12.0 | -7.6 | -7.0 | -6.0 | +2.5 | +11.1 | +0.7 |
| 2023 | +1.9 | +1.4 | -2.7 | +16.5 | -8.5 | +7.8 | -0.7 | -10.1 | -7.8 | -7.5 | +16.3 | +3.4 |
| 2024 | +4.4 | -6.9 | -4.0 | -1.7 | +4.9 | -1.7 | +17.4 | +0.3 | +1.5 | -18.6 | +2.1 | -4.5 |
| 2025 | +4.0 | +14.2 | -4.3 | -0.6 | +2.6 | +5.1 | -0.1 | +21.5 | -1.7 | +0.1 | -9.5 | +0.3 |
| 2026 | +3.8 | +7.7 | -11.1 | -3.6 | -4.7 | -2.3 | +9.9 | -10.5 | -6.9 | +11.7 | +3.0 |
Corporate actions
Upcoming
No upcoming corporate actions for SNN



